CREBZF

Summary

CREBZF (CREB/ATF bZIP transcription factor, HGNC:24905) is a protein-coding gene on chromosome 11q14.1, encoding CREB/ATF bZIP transcription factor (Q9NS37). Strongly activates transcription when bound to HCFC1.

Enables identical protein binding activity. Involved in negative regulation of gene expression, epigenetic; regulation of DNA-templated transcription; and response to virus. Located in mitochondrion and nucleoplasm. Part of RNA polymerase II transcription regulator complex.

Source: NCBI Gene 58487 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 52 total
• Transcription factor: yes — 22 downstream targets (CollecTRI)
• MANE Select transcript: NM_001039618

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24905
Approved symbol	CREBZF
Name	CREB/ATF bZIP transcription factor
Location	11q14.1
Locus type	gene with protein product
Status	Approved
Aliases	ZF, SMILE
Ensembl gene	ENSG00000137504
Ensembl biotype	protein_coding
OMIM	606444
Entrez	58487

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 nonsense_mediated_decay, 2 protein_coding, 2 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000260058, ENST00000490820, ENST00000525639, ENST00000527447, ENST00000527529, ENST00000528561, ENST00000528889, ENST00000531515, ENST00000534224, ENST00000682836, ENST00000850607

RefSeq mRNA: 1 — MANE Select: NM_001039618 NM_001039618

CCDS: CCDS41697

Canonical transcript exons

ENST00000527447 — 1 exons

Exon	Start	End
ENSE00004282314	85657990	85665129

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 95.80.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 36.1545 / max 407.9332, expressed in 1813 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
121685	33.6174	1812
121684	0.9690	654
121686	0.6626	265
121682	0.5571	218
121683	0.3485	189

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	95.80	gold quality
adrenal tissue	UBERON:0018303	95.72	gold quality
left ovary	UBERON:0002119	95.71	gold quality
right ovary	UBERON:0002118	95.41	gold quality
body of uterus	UBERON:0009853	95.39	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.87	gold quality
cardia of stomach	UBERON:0001162	94.78	gold quality
cerebellar hemisphere	UBERON:0002245	94.72	gold quality
cerebellar cortex	UBERON:0002129	94.58	gold quality
ventricular zone	UBERON:0003053	94.53	gold quality
right lung	UBERON:0002167	94.47	gold quality
endocervix	UBERON:0000458	94.44	gold quality
left lobe of thyroid gland	UBERON:0001120	94.30	gold quality
fundus of stomach	UBERON:0001160	94.29	gold quality
left uterine tube	UBERON:0001303	94.29	gold quality
pylorus	UBERON:0001166	94.27	gold quality
ganglionic eminence	UBERON:0004023	94.19	gold quality
nerve	UBERON:0001021	94.13	gold quality
tibial nerve	UBERON:0001323	94.13	gold quality
ovary	UBERON:0000992	94.11	gold quality
body of pancreas	UBERON:0001150	94.11	gold quality
tibial artery	UBERON:0007610	93.91	gold quality
popliteal artery	UBERON:0002250	93.90	gold quality
right lobe of thyroid gland	UBERON:0001119	93.88	gold quality
small intestine Peyer’s patch	UBERON:0003454	93.80	gold quality
thyroid gland	UBERON:0002046	93.79	gold quality
artery	UBERON:0001637	93.72	gold quality
right coronary artery	UBERON:0001625	93.61	gold quality
right uterine tube	UBERON:0001302	93.54	gold quality
mucosa of stomach	UBERON:0001199	93.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.33

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

22 targets.

Target	Regulation
ACACA
AP3B1
BGLAP
CD86
CREBZF
ESRRG
FASN
FPR2
GAST
HCFC1
INS
NR1H3
NTRK1	Activation
PDK4	Repression
PPARGC1B
PRKAA1
SERPINB5
SREBF1	Repression
STK11
TERT
TSHB
WT1

Upstream regulators (CollecTRI, top): CREBZF, ESR1, ESRRG, SSRP1

miRNA regulators (miRDB)

360 targeting CREBZF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-511-3P	99.99	68.85	1467

Literature-anchored findings (GeneRIF, showing 23)

• ZF suppresses the ability of Luman/CREB3 to activate gene expression (PMID:15705566)
• ZF suppresses the ability of VP16 to activate herpes simplex virus IE gene expression (PMID:16282471)
• ZF binds ATF4/CREB2 and enhances its response to MEK1 activation. (PMID:16343488)
• These results indicate that SMILE isoforms regulate the inhibition of estrogen receptor transactivation by SHP in a cell-type-specific manner and act as a novel transcriptional co-regulator in ER signalling. (PMID:18657049)
• Zhangfei causes medulloblastoma cells to undergo apoptosis (PMID:18719857)
• findings showed Zhangfei activated the expression of trkA and Egr1 in medulloblastoma cells and caused these cells to display markers of apoptosis (PMID:18719857)
• In differentiated PC12 cells, Zhangfei activated the trkA promoter and induced the expression of endogenous trkA. (PMID:19016376)
• SMILE is a novel corepressor of ERRgamma, and SIRT1 has a role as a novel repressive mechanism for SMILE and ERRgamma inverse agonist (PMID:19690166)
• SMILE is involved in the endoplasmic reticulum stress response, by modulating proteasome activity and XBP-1 transcript expression. This function of SMILE may influence immune cell behavior in the context of transplantation. (PMID:21603654)
• the curcumin/LKB1/AMPK/SMILE/PGC1alpha pathway differentially regulates ER stress-mediated gene transcription (PMID:21994947)
• a microarray study of SMILE knock-down and PMA activation in HeLa cells was compared to earlier analysis based on microarray data of kidney allograft tolerance and rejection to determine possible new genes and gene networks involved in kidney transplantation (PMID:22134986)
• CREBZF, a novel Smad8-binding protein. (PMID:22707059)
• Our objective was to determine the molecular mechanisms by which Zhangfei influences medulloblastoma cell lines (PMID:22798206)
• The transcription factor CREBZF is a novel positive regulator of p53. (PMID:22983008)
• Zhangfei had a suppressive effect on most unfolded protein response genes. (PMID:24155933)
• Zhangfei/CREBZF stabilizes p53 and co-localizes with it in cellular nuclei; the bLZip domain of Zhangfei is required for its profound effects on cell growth and interaction with p53. (PMID:24200963)
• Results indicate that Ursodeoxycholic acid (UDCA) activates SMILE gene expression, which leads to repression of liver X receptor alpha (LXRalpha)-mediated hepatic lipogenic enzyme gene expression. (PMID:24265317)
• miRNAs as potential biomarkers for the progression of gastric cancer inhibit CREBZF and regulate migration of gastric adenocarcinoma cells. (PMID:32218690)
• Up-regulation of long noncoding RNA MBNL1-AS1 suppresses breast cancer progression by modulating miR-423-5p/CREBZF axis. (PMID:35094653)
• SMILE Downregulation during Melanogenesis Induces MITF Transcription in B16F10 Cells. (PMID:36499416)
• Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression. (PMID:36680394)
• When molecular outsmarts morphology: Malignant ossifying fibromyxoid tumors masquerading as osteosarcomas, including a novel CREBZF::PHF1 fusion. (PMID:37819540)
• Macrophage CREBZF Orchestrates Inflammatory Response to Potentiate Insulin Resistance and Type 2 Diabetes. (PMID:38286660)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	crebzf	ENSDARG00000089787
mus_musculus	Crebzf	ENSMUSG00000051451
rattus_norvegicus	Crebzf	ENSRNOG00000018987

Protein

Protein identifiers

CREB/ATF bZIP transcription factor — Q9NS37 (reviewed: Q9NS37)

Alternative names: Host cell factor-binding transcription factor Zhangfei

All UniProt accessions (4): Q9NS37, E9PIM0, H0YDC7, J3KN20

UniProt curated annotations — full annotation on UniProt →

Function. Strongly activates transcription when bound to HCFC1. Suppresses the expression of HSV proteins in cells infected with the virus in a HCFC1-dependent manner. Also suppresses the HCFC1-dependent transcriptional activation by CREB3 and reduces the amount of CREB3 in the cell. Able to down-regulate expression of some cellular genes in CREBZF-expressing cells.

Subunit / interactions. Interacts with HCFC1; the interaction inhibits CREB3 transcriptional activity. Interacts with CREB3; the interaction occurs only in combination with HCFC1.

Subcellular location. Nucleus.

Tissue specificity. In adults, expressed most abundantly in heart, liver and skeletal muscle, moderately abundant in kidney and pancreas, and barely detectable in lung. In fetal tissues, expressed most abundantly in kidney and very low amounts in heart, lung and liver.

Miscellaneous. Named ‘Zhangfei’ after a legendary Chinese warrior who was contemporary with Luman in around 220 AD.

Similarity. Belongs to the bZIP family. ATF subfamily.

RefSeq proteins (1): NP_001034707* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004827	bZIP	Domain
IPR046347	bZIP_sf	Homologous_superfamily

Pfam: PF00170

UniProt features (17 total): region of interest 5, compositionally biased region 4, mutagenesis site 3, chain 1, domain 1, modified residue 1, sequence conflict 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NS37-F1	62.65	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 50

Mutagenesis-validated functional residues (3):

Position	Phenotype
303	significantly reduced binding to hcfc1.
304	significantly reduced binding to hcfc1.
306	does not interact with hcfc1 and is inefficient at inhibiting creb3 transcriptional activity. does not colocalize with c

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 308 (showing top): AHRARNT_01, GGGACCA_MIR133A_MIR133B, MODULE_97, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, PAX4_01, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, MODULE_182, GGAMTNNNNNTCCY_UNKNOWN, GOBP_CELLULAR_RESPONSE_TO_TOPOLOGICALLY_INCORRECT_PROTEIN, ATGTTAA_MIR302C, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, NFKB_Q6, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, CATTTCA_MIR203

GO Biological Process (9): regulation of transcription by RNA polymerase II (GO:0006357), response to virus (GO:0009615), ATF6-mediated unfolded protein response (GO:0036500), negative regulation of gene expression, epigenetic (GO:0045814), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), obsolete regulation of DNA-binding transcription factor activity (GO:0051090), integrated stress response signaling (GO:0140467), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), identical protein binding (GO:0042802), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (5): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), mitochondrion (GO:0005739), RNA polymerase II transcription regulator complex (GO:0090575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
transcription by RNA polymerase II	2
DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
cellular anatomical structure	2
intracellular membrane-bounded organelle	2
response to other organism	1
ER-nucleus signaling pathway	1
endoplasmic reticulum unfolded protein response	1
negative regulation of gene expression	1
epigenetic regulation of gene expression	1
negative regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
cellular response to stress	1
intracellular signaling cassette	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
nucleic acid binding	1
protein binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
chromosome	1
nuclear lumen	1
cytoplasm	1
transcription regulator complex	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1122 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CREBZF	HCFC1	P51610	985
CREBZF	HCFC2	Q9Y5Z7	971
CREBZF	CREB3	O43889	881
CREBZF	CREB3L4	Q8TEY5	790
CREBZF	NR0B2	Q15466	668
CREBZF	POU2F1	P14859	587
CREBZF	CANX	P27824	492
CREBZF	HP1BP3	Q5SSJ5	454
CREBZF	ATF4	P18848	449
CREBZF	SMAD9	O15198	429
CREBZF	DPF3	Q92784	412
CREBZF	DCDC2	Q9UHG0	400
CREBZF	EDF1	O60869	395
CREBZF	REL	Q04864	393
CREBZF	ARPC2	O15144	393

IntAct

86 interactions, top by confidence:

A	B	Type	Score
BACH1	MAFG	psi-mi:“MI:0914”(association)	0.870
CREBZF	CREBZF	psi-mi:“MI:0407”(direct interaction)	0.810
CREBZF	CREBZF	psi-mi:“MI:0915”(physical association)	0.810
HCFC1	CREB3	psi-mi:“MI:0915”(physical association)	0.800
CREB3	HCFC1	psi-mi:“MI:0407”(direct interaction)	0.800
CREBZF	ATF4	psi-mi:“MI:0407”(direct interaction)	0.780
CREBZF	ATF4	psi-mi:“MI:0915”(physical association)	0.780
ATF4	CREBZF	psi-mi:“MI:0915”(physical association)	0.780
ATF4	CREBZF	psi-mi:“MI:0407”(direct interaction)	0.780
CREBZF	HCFC1	psi-mi:“MI:0915”(physical association)	0.770
HCFC1	CREBZF	psi-mi:“MI:0915”(physical association)	0.770
CREBZF	HCFC1	psi-mi:“MI:0407”(direct interaction)	0.770
RALBP1	CREBZF	psi-mi:“MI:0915”(physical association)	0.740
RALBP1	JUN	psi-mi:“MI:0914”(association)	0.640
NFE2L2	CREBZF	psi-mi:“MI:0915”(physical association)	0.630
CREBZF	XBP1	psi-mi:“MI:0407”(direct interaction)	0.620

BioGRID (43): CREBZF (Two-hybrid), CREBZF (Two-hybrid), TTC23 (Two-hybrid), CREBZF (Affinity Capture-RNA), CREBZF (Affinity Capture-RNA), CREBZF (Affinity Capture-MS), CREBZF (Affinity Capture-MS), CREBZF (Affinity Capture-MS), CREBZF (Reconstituted Complex), TP53 (Reconstituted Complex), CREBZF (Affinity Capture-RNA), CREBZF (Affinity Capture-RNA), CREBZF (Two-hybrid), CREBZF (Two-hybrid), HCFC1 (Two-hybrid)

ESM2 similar proteins: A0A0N7KIY3, A0A2R6QE26, A2X674, A2X7U1, A2XE76, A2Y931, A2YW03, A2Z4C4, A3B6V0, D0PX88, O22768, P13027, P13526, P26307, P37398, Q01I23, Q0E0A6, Q0JB92, Q0JEB7, Q10S44, Q2QX40, Q336P5, Q336V8, Q338Z7, Q40691, Q5JMK6, Q5JNS0, Q5QNI5, Q5UG13, Q5VPE3, Q5VPE5, Q67UE2, Q6AT90, Q6H6S3, Q6K3R9, Q6YPD0, Q6YUS3, Q75KV9, Q7G737, Q7X8R0

Diamond homologs: Q91ZR3, Q9NS37

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cellular responses to stress	7	13.6×	4e-05
Cellular responses to stimuli	7	11.6×	8e-05

GO biological processes:

GO term	Partners	Fold	FDR
integrated stress response signaling	5	117.0×	1e-07
endoplasmic reticulum unfolded protein response	6	59.1×	1e-07
response to endoplasmic reticulum stress	5	27.8×	8e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

290 predictions. Top by Δscore:

Variant	Effect	Δscore
11:85663806:TG:T	donor_gain	0.9800
11:85663874:AT:A	donor_gain	0.9800
11:85662464:C:CT	acceptor_gain	0.9700
11:85663860:TC:T	donor_gain	0.9300
11:85663861:CC:C	donor_gain	0.9300
11:85663865:CGA:C	donor_gain	0.9200
11:85662456:CACTT:C	acceptor_gain	0.9100
11:85663175:TC:T	donor_gain	0.9000
11:85663837:T:TA	donor_gain	0.9000
11:85663813:A:AC	donor_gain	0.8700
11:85663814:C:CC	donor_gain	0.8700
11:85663601:ACTGT:A	acceptor_gain	0.8500
11:85663602:CTGT:C	acceptor_gain	0.8500
11:85663875:T:C	donor_gain	0.8500
11:85663600:AACTG:A	acceptor_gain	0.8400
11:85663173:CT:C	donor_gain	0.8300
11:85663174:TT:T	donor_gain	0.8300
11:85663277:GCT:G	acceptor_gain	0.8300
11:85663603:T:A	acceptor_gain	0.8300
11:85663282:G:GT	acceptor_gain	0.8200
11:85663283:T:TT	acceptor_gain	0.8200
11:85663599:AAACT:A	acceptor_gain	0.8200
11:85663800:A:AC	donor_gain	0.8200
11:85662385:C:CT	donor_gain	0.7800
11:85662386:T:TT	donor_gain	0.7800
11:85663278:C:A	acceptor_gain	0.7700
11:85662458:C:CC	acceptor_gain	0.7600
11:85662459:T:C	acceptor_gain	0.7500
11:85663291:AGTCT:A	acceptor_gain	0.7500
11:85663292:GTCTG:G	acceptor_gain	0.7500

AlphaMissense

2263 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:85663844:G:C	C344W	1.000
11:85663845:C:T	C344Y	1.000
11:85663846:A:G	C344R	1.000
11:85663853:G:C	C341W	1.000
11:85663854:C:T	C341Y	1.000
11:85663855:A:G	C341R	1.000
11:85663857:A:G	F340S	1.000
11:85663867:A:G	S337P	1.000
11:85663888:G:C	H330D	1.000
11:85663890:A:G	L329P	1.000
11:85663890:A:T	L329H	1.000
11:85663892:A:C	C328W	1.000
11:85663893:C:G	C328S	1.000
11:85663893:C:T	C328Y	1.000
11:85663894:A:G	C328R	1.000
11:85663894:A:T	C328S	1.000
11:85664067:A:T	V270D	1.000
11:85664076:A:G	L267P	1.000
11:85664097:A:G	L260P	1.000
11:85664139:A:G	L246P	1.000
11:85664160:A:G	L239P	1.000
11:85664181:A:G	L232P	1.000
11:85664193:T:C	Y228C	1.000
11:85664198:C:A	K226N	1.000
11:85664198:C:G	K226N	1.000
11:85664201:C:A	K225N	1.000
11:85664201:C:G	K225N	1.000
11:85664208:A:G	L223P	1.000
11:85664212:G:C	R222G	1.000
11:85664223:G:T	A218D	1.000

dbSNP variants (sampled 300 via entrez): RS1000136799 (11:85679274 A>G,T), RS1000196118 (11:85676825 G>A,T), RS1000207324 (11:85680675 T>A,C), RS1000248801 (11:85682692 G>A,C), RS1000365462 (11:85682839 A>T), RS1000487547 (11:85679523 T>C,G), RS1000515093 (11:85663237 C>A,G,T), RS1000569497 (11:85683793 C>T), RS1000815140 (11:85681579 G>A), RS1000897710 (11:85663733 T>C,G), RS1000947660 (11:85659039 C>CAT), RS1001199997 (11:85671963 T>C), RS1001214455 (11:85675391 G>A), RS1001296904 (11:85678644 TTC>T), RS1001332441 (11:85675692 G>A,C)

Disease associations

OMIM: gene MIM:606444 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_244	Refractive error	2.000000e-53

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression	3
trichostatin A	affects cotreatment, decreases expression	2
perfluorooctane sulfonic acid	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
tetrathiomolybdate	increases expression	1
potassium chromate(VI)	affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	increases expression	1
2-palmitoylglycerol	increases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases expression, decreases reaction	1
dorsomorphin	affects cotreatment, decreases expression	1
Vehicle Emissions	decreases reaction, decreases expression	1
Benzo(a)pyrene	affects methylation	1
Cisplatin	decreases expression	1
Demecolcine	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	increases expression	1
Methyl Methanesulfonate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.